SCHEMBL5460515

SCHEMBL5460515

CCC1CCc2c(sc(NC(=O)C3CC3C)c2C(N)=O)C1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AIP O00170 1/20 0.69
SGTA O43765 1/20 0.69
TOMM70 O94826 1/20 0.69
STIP1 P31948 1/20 0.69
PPP5C P53041 1/20 0.69
DNAJC7 Q99615 1/20 0.69
STUB1 Q9UNE7 1/20 0.69
TNIK Q9UKE5 1/20 0.63
ALDH1A1 P00352 7/20 0.62
KDM4E B2RXH2 5/20 0.62
HPGD P15428 5/20 0.62
MAPT P10636 7/20 0.60
SMN1; SMN2 Q16637 4/20 0.60
RAB9A P51151 4/20 0.60
NPC1 O15118 3/20 0.60
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
TP53 P04637 1/20 0.60
HTT P42858 1/20 0.60
USP2 O75604 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5451305 0.86 MAPT (0.70) ALDH1A1KDM4EHPGDMAPTRAB9A
SCHEMBL5453282 0.85 AIP (0.71) AIPSGTATOMM70STIP1PPP5C
SCHEMBL5451446 0.85 AIP (0.71) AIPSGTATOMM70STIP1PPP5C
SCHEMBL5453580 0.85 MAPT (0.56) AIPSGTATOMM70STIP1PPP5C
SCHEMBL5461038 0.80 FLT3 (0.70) ALDH1A1KDM4EHPGDMAPTSMN1; SMN2
SCHEMBL5454136 0.79 REV1 (0.81) AIPSGTATOMM70STIP1PPP5C
SCHEMBL5453185 0.77 FLT3 (0.65) AIPSGTATOMM70STIP1PPP5C
SCHEMBL5447651 0.77 FLT3 (0.65) AIPSGTATOMM70STIP1PPP5C
SCHEMBL5453129 0.77 PTPN1 (0.50) AIPSGTATOMM70STIP1PPP5C
SCHEMBL5460380 0.77 CFTR (0.60) ALDH1A1KDM4EHPGDMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 AIP 3230/4885SGTA 3685/4885TOMM70 1575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.